Vor Biopharma
Main focus: Cell therapies for cancer treatment
Company stage: Clinical
Diseases: Acute myeloid leukaemia (AML)
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:VOR)
Location: Cambridge, MA, USA
Website: https://www.vorbio.com/
Pipeline: https://www.vorbio.com/focus-pipeline/
Partners: Metagenomi
Vor Biosciences is a clinical-stage cell therapy company, with a focus on delivering innovate medicines against cancer, with a primary focus on acute myeloid leukaemia. The company uses its proprietary Vor platform to discover novel targets such as CD123 and CLL-1. The company also uses the platform to discover new targets for non-myeloid malignancies. The company is focused on developing engineered haematopoetic stem cells (eHSC) and CAR-T cells as well as a synergetic treatment using a combination of the two technologies.